Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2023 event, please get in touch at email@example.com
In the last 18-24 months, catapulted by the urgency and opportunity to treat more homogenous COVID patient populations, the ARDS drug development field has spiked. As stakeholders with pipeline MScs, inflammation, and respiratory expand into ARDS, now is the time to finally advance therapeutics for this indication beyond the historical challenges, and harness the urgency and opportunity of a large unmet patient need.
The 2nd ARDS Drug Development Summit is the only industry-led meeting bringing together 80+ biopharma, pharmaceutical, and academic thought leaders dedicated to understanding and addressing acute respiratory distress syndrome.
With conversations covering early endpoints in clinical trials to benchmark, troubleshoot, and confidently verify proof of concept; get up to date on the hottest ARDS research, and network with leaders at this exclusive industry-specific conference. Spanning 3 days of thought-provoking content, leave this meeting with the actionable insights you need to supercharge your drug development
Access the full event guide here to see the agenda and speaker faculty.
|Navigate the complexity of patient pathways in ARDS clinical trial design to achieve well-controlled, successful studies with Biomarck Pharmaceuticals, Edesa Biotech, and Tetra Biopharma|
|Illuminate multi-modal, practical, ARDS phenotyping to develop innovative ARDS precision therapies with Washington University, Harvard Medical School, and Amsterdam UMC|
|Explore the similarities and differences between COVID-19 ARDS and Non-COVID ARDS and explore lessons learned from the past couple of years to consolidate fundamental understandings of the disease to revolutionize drug development with Apeptico, Augusta University, Partner Therapeutics, and Virginia University|
|Leveraging the experiences of the ARDS drug development landscape to unlock novel therapeutic modalities that mirror the heterogeneity of ARDS patients with Healios K.K., Gen1E Life Sciences, and Aptarion Biotech|
Academics & Clinicians